The leader of the pharmaceutical market: how Darnitsa earned a record in procurement for the army
18 June 21:03
In 2024, the pharmaceutical company “Darnitsa” earned UAH 196 million at public tenders, which is more than twice as much as in the previous year. This is evidenced by the data of the Opendatabot portal with reference to the Prozorro electronic public procurement system, "Komersant Ukrainian" reports.
The company received the most profit from the supply of medicines to military institutions. In particular, the company supplied medicines worth UAH 62 million to the Main Military Clinical Hospital alone. This is almost a third of the total amount received during the year from tenders.
The key factors behind this growth were
- the government’s reorientation towards domestic producers during the full-scale war;
- simplification of procurement procedures due to military needs;
- prompt deliveries, which favorably distinguishes local producers from international suppliers facing logistical barriers.
However, there are also nuances. According to Proxima Research, in two years Darnitsa has increased the prices for one of the most popular medicines, Citramon, by 120%.
As of the first five months of 2025, Darnitsa has already earned UAH 48 million from public tenders. The growth rate indicates the company’s consistent expansion into the public procurement market, especially in the defense and medical sectors.
As of the end of 2024, the company also demonstrates a stable growth of financial indicators. Darnitsa’s net revenue amounted to UAH 6.9 billion and net profit amounted to UAH 377 million. Although this figure is somewhat lower than in 2023 (when the net profit exceeded UAH 1.3 billion), analysts attribute this to the general redistribution of costs, in particular investments in logistics and production.
However, despite the growth in revenue, the company’s net profit in 2024 decreased to UAH 377 million, which is 70% less than in 2023. This may be due to:
- rising production costs;
- inflationary pressure on components and raw materials;
- targeted investments in production modernization or logistics;
- pricing policy within the framework of public procurement, where the price is often lower than the market price.
“Darnitsa is one of the largest Ukrainian manufacturers of medicinal products. The company is actively expanding its product range, focusing on the production of critical medicines, including cardiology, neurology, painkillers and antibiotics. Market participants note that since the beginning of the full-scale war, Darnitsa has also increased the supply of medicines for the needs of the Armed Forces and medical institutions in the frontline regions.
Experts explain the growth of participation in public procurement not only by the expansion of production capacities, but also by the company’s active communication with government agencies. In 2024, Darnitsa also strengthened its cooperation with the National Health Service of Ukraine and the Ministry of Defense.
Читайте нас у Telegram: головні новини коротко
